{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:08:52Z","timestamp":1753891732959,"version":"3.41.2"},"reference-count":45,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2017.00454","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T03:53:13Z","timestamp":1504583593000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions"],"prefix":"10.3389","volume":"8","author":[{"given":"Ruth","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Bellenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hoepner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisa","family":"Ellrichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/s1473-3099(09)70226-9","article-title":"Progressive multifocal leukoencephalopathy in HIV-1 infection","volume":"9","author":"Cinque","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/jnnp-2015-311411","article-title":"MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS","volume":"87","author":"Wattjes","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0168376","DOI":"10.1371\/journal.pone.0168376","article-title":"Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry","volume":"11","author":"Prosperini","year":"2016","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/jnnp-2013-304897","article-title":"Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients","volume":"84","author":"Dahlhaus","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/jnnp-2013-304986","article-title":"Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?","volume":"84","author":"Wattjes","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab","volume":"71","author":"Kleinschmidt-DeMasters","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","article-title":"Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?","volume":"79","author":"Antoniol","year":"2012","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s13365-014-0289-8","article-title":"Progressive multifocal leukoencephalopathy therapy","volume":"21","author":"Clifford","year":"2015","journal-title":"J Neurovirol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1177\/1352458513510224","article-title":"The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"19","author":"Wattjes","year":"2013","journal-title":"Mult Scler"},{"key":"B17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1602\/neurorx.2.2.197","article-title":"Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making","volume":"2","author":"Lin","year":"2005","journal-title":"NeuroRx"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1212\/WNL.0b013e318268465b","article-title":"Metabolic profile of PML lesions in patients with and without IRIS: an observational study","volume":"79","author":"Gheuens","year":"2012","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/j.1468-1331.2011.03597.x","article-title":"Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis","volume":"19","author":"Sahraian","year":"2012","journal-title":"Eur J Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00062-013-0216-z","article-title":"A case of natalizumab-associated progressive multifocal leukoencephalopathy \u2013 role for advanced MRI?","volume":"24","author":"Berghoff","year":"2014","journal-title":"Clin Neuroradiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"415873","DOI":"10.1155\/2013\/415873","article-title":"Early magnetic resonance detection of natalizumab-related progressive multifocal leukoencephalopathy in a patient with multiple sclerosis","volume":"2013","author":"Manenti","year":"2013","journal-title":"Case Rep Radiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0176415","DOI":"10.1371\/journal.pone.0176415","article-title":"Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)","volume":"12","author":"Schneider","year":"2017","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/wco.0000000000000200","article-title":"Neurological immune reconstitution inflammatory response: riding the tide of immune recovery","volume":"28","author":"Clifford","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/1352458516667241","article-title":"Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"23","author":"Hoepner","year":"2017","journal-title":"Mult Scler"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N Engl J Med"},{"key":"B27","first-page":"196","article-title":"The clinical evaluation of chemotherapeutic agents in cancer","volume-title":"Evaluation of Chemotherapeutic Agents","author":"Karnofsky","year":"1949"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"E156","DOI":"10.3174\/ajnr.A2305","article-title":"Proton MR spectroscopy in a 1T open MR imaging system","volume":"32","author":"Filippi","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11547-009-0408-4","article-title":"Computation of brain metabolite ratios in single-voxel proton MR spectroscopy: comparison between semiautomatic and automatic software","volume":"115","author":"Mazzoni","year":"2010","journal-title":"Radiol Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1161\/strokeaha.107.507020","article-title":"Choline and creatine are not reliable denominators for calculating metabolite ratios in acute ischemic stroke","volume":"39","author":"Munoz Maniega","year":"2008","journal-title":"Stroke"},{"key":"B32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bbacli.2016.04.002","article-title":"Magnetic resonance spectroscopy \u2013 revisiting the biochemical and molecular milieu of brain tumors","volume":"5","author":"Verma","year":"2016","journal-title":"BBA Clin"},{"key":"B33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/1531-8249(199907)46:1<79::AID-ANA12>3.0.CO;2-9","article-title":"Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy","volume":"46","author":"van Walderveen","year":"1999","journal-title":"Ann Neurol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/jnnp.68.5.627","article-title":"Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations","volume":"68","author":"Brex","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/00401706.1964.10490181","article-title":"Multiple comparisons using rank sums","volume":"6","author":"Dunn","year":"1964","journal-title":"Technometrics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/nbm.1661","article-title":"MR-visible lipids and the tumor microenvironment","volume":"24","author":"Delikatny","year":"2011","journal-title":"NMR Biomed"},{"key":"B37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/immu.1994.1014","article-title":"Two-dimensional 1H NMR studies of membrane changes during the activation of primary T lymphocytes","volume":"4","author":"Dingley","year":"1994","journal-title":"Immunomethods"},{"key":"B38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/brain\/124.5.953","article-title":"Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis","volume":"124","author":"Mader","year":"2001","journal-title":"Brain"},{"key":"B39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.nic.2008.08.002","article-title":"Proton magnetic resonance spectroscopy in multiple sclerosis","volume":"19","author":"Sajja","year":"2009","journal-title":"Neuroimaging Clin N Am"},{"key":"B40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mrm.10332","article-title":"Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases","volume":"49","author":"Seeger","year":"2003","journal-title":"Magn Reson Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00415-002-0846-6","article-title":"Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis","volume":"249","author":"Tartaglia","year":"2002","journal-title":"J Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0162583","DOI":"10.1371\/journal.pone.0162583","article-title":"Brain metabolite changes in patients with relapsing-remitting and secondary progressive multiple sclerosis: a two-year follow-up study","volume":"11","author":"Obert","year":"2016","journal-title":"PLoS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/ana.410360207","article-title":"Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging","volume":"36","author":"Husted","year":"1994","journal-title":"Ann Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/mrm.1910360113","article-title":"Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T","volume":"36","author":"Pan","year":"1996","journal-title":"Magn Reson Med"},{"key":"B45","first-page":"1619","article-title":"Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy","volume":"20","author":"Bitsch","year":"1999","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T03:53:14Z","timestamp":1504583594000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":45,"alternative-id":["10.3389\/fneur.2017.00454"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2017.00454","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2017,9,5]]},"article-number":"454"}}